Table 1. Characteristics of the patient samples included in the study.
| Cured acromegaly (N = 20) | Naïve acromegaly (N = 20) | |
| Age at diagnosis, mean (SD) | 46.40 (11.08) | 48.50 (10.25) |
| GH (µg/liter), mean (SD) | 0.40 (0.51) | 16.32 (14.72) |
| IGF-I (µg/liter), mean (SD) | 179.63 (104.70) | 1022.28 (507.16) |
| IGF-ISD, mean (SD) | 0.37 (1.83) | 16.29 (8.39) |
| Prolactin (µg/liter), mean (SD) | 7.22 (3.41) | 25.03 (30.27) |
| Surgery, n (% of patients) | ||
| Transphenoidal | 20 (100) | 0 |
| No | 0 | 20 (100) |
| Comorbidities, n (% of patients) | ||
| Myocardiopathy | 2 (10) | 2 (10) |
| Hypertensiona | 5 (25) | 10 (50) |
| Arthralgia | 2 (10) | 2 (10) |
| Carpal tunnel syndrome | 1 (5) | 6 (30) |
| Diabetes mellitusb | 2 (10) | 4 (20) |
| Sleep apnea | 1 (5) | 5 (25) |
| Malignancy | 1c (5) | 0 |
| Dyslipidemia | 3 (15) | 4 (20) |
| Gallstones | 1 (5) | 4 (20) |
| Hypopituitarism (any axis) | 8 (40) | 4 (20) |
| ACTH | 2 (10) | 2 (10) |
| TSH | 5 (25) | 2 (10) |
| FSH/LH | 5 (25) | 1 (5) |
| Depression | 6 (30) | 3 (15) |
| Tumor characteristics, n (% of patients) | ||
| Macroadenoma | 13 (65) | 17 (85) |
| Microadenoma | 7 (35) | 3 (15) |
| Suprasellar extension | 4 (20) | 4 (20) |
| Cavernous sinus extension | 7 (35) | 7 (35) |
| Sphenoid sinus extension | 0 | 2 (10) |
| GH secreting adenoma | 14 (70) | n/a |
| Mixed GH/PRL secreting adenoma | 6 (30) | n/a |
| Duration of untreated disease, mean months (SD) | 59.65 (55.79) | 59.32 (40.88) |
| Duration of biochemical remission mean months (SD) | 95.73 (59.01) | n/a |
| AcroQoL scored | 31.85 (25.28) | 42.82 (24.40) |
a
Treatment in the cured acromegaly group (n): angiotensin-converting enzyme inhibitors (4); angiotensin II type 1 receptor blockers (1). Treatment in the naïve acromegaly group: angiotensin-converting enzyme inhibitors (6); calcium channel blocker (3); angiotensin II type 1 receptor blockers (1).
b
All the patients were treated with metformin for diabetes. Only one patient (cured acromegaly) required additional insulin treatment.
c
Colorectal cancer.
d
The higher the score in this questionnaire, the worse self-perceived QoL is.